Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG monthly Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-3.93 Insider Own2.00% Shs Outstand53.73M Perf Week1.38%
Market Cap2.60B Forward P/E- EPS next Y-4.17 Insider Trans-12.68% Shs Float33.18M Perf Month-1.33%
Income-200.40M PEG- EPS next Q-0.95 Inst Own51.10% Short Float14.80% Perf Quarter6.43%
Sales1.30M P/S1997.52 EPS this Y-101.60% Inst Trans5.61% Short Ratio9.85 Perf Half Y35.80%
Book/sh6.91 P/B6.99 EPS next Y-8.00% ROA-40.10% Target Price62.13 Perf Year-6.86%
Cash/sh7.96 P/C6.07 EPS next 5Y- ROE-51.50% 52W Range22.22 - 53.90 Perf YTD69.16%
Dividend- P/FCF- EPS past 5Y- ROI-40.70% 52W High-10.33% Beta-
Dividend %- Quick Ratio14.00 Sales past 5Y- Gross Margin- 52W Low117.51% ATR1.95
Employees188 Current Ratio14.00 Sales Q/Q-72.70% Oper. Margin- RSI (14)52.48 Volatility4.06% 4.36%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.20% Profit Margin- Rel Volume0.53 Prev Close47.51
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout- Avg Volume498.39K Price48.33
Recom2.30 SMA202.84% SMA500.27% SMA20021.35% Volume263,080 Change1.73%
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Sep-21-19 08:37AM  CRISPR Therapeutics (NASDAQ:CRSP) Is In A Strong Position To Grow Its Business Simply Wall St.
Sep-17-19 07:00AM  CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019 GlobeNewswire
Sep-05-19 03:07PM  Probability 101: How Not to Be a Sucker Zacks
Aug-27-19 09:10AM  CRISPR gene-editing technique set to push new boundaries MarketWatch
Aug-26-19 11:34PM  Gene editing: even Crispr Financial Times
Aug-07-19 09:32AM  Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO Zacks
Aug-06-19 10:04AM  Vertex Has "Significant Financial Firepower" Motley Fool +5.56%
Aug-01-19 12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
06:16AM  Legal fight over Broad Institute's patent for CRISPR gene editing flares up again American City Business Journals
Jul-31-19 12:41PM  Is Intellia Therapeutics a Buy? Motley Fool
07:01AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jul-29-19 05:45PM  CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
11:40AM  Axovant (AXGT) to Post Q1 Earnings: What's in the Cards? Zacks
Jul-26-19 11:49AM  Vertex (VRTX) to Post Q2 Earnings: What's in the Cards? Zacks
Jul-25-19 11:20AM  Where Will CRISPR Therapeutics Be in 5 Years? Motley Fool
Jul-24-19 10:25AM  Jim Cramer Gives His Opinion On eBay, Pfizer And More Benzinga
Jul-23-19 05:03PM  Is Vertex Pharmaceuticals a Buy? Motley Fool
04:44PM  CRISPR Could Change Medicine, But Not in the Way Wall Street Expects Motley Fool
Jul-18-19 09:00AM  2 Supercharged Growth Stocks I'd Buy Right Now Motley Fool
Jul-17-19 03:40PM  Can We Find The Right Stock Using Our Newly Found Insight? Zacks
Jul-16-19 06:05PM  Should You Pick Up Novartis (NVS) Before Q2 Earnings? Zacks
10:07AM  Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA Zacks
Jul-11-19 04:26PM  Getting technical: Buyers in control of Crispr Therapeutics (CRSP) Yahoo Finance Video
Jul-10-19 08:16AM  Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June Motley Fool
Jul-01-19 04:01PM  CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes GlobeNewswire
Jun-29-19 04:35PM  3 Growth Stocks to Buy and Hold for the Next 50 Years Motley Fool
Jun-28-19 09:42PM  Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ? Insider Monkey
Jun-23-19 10:48AM  What Kind Of Shareholders Own CRISPR Therapeutics AG (NASDAQ:CRSP)? Simply Wall St.
10:45AM  How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own? Simply Wall St.
Jun-18-19 09:15AM  Fed Week Begins in the Green Zacks
Jun-13-19 01:43PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns definitive ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
10:47AM  Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray American City Business Journals
Jun-12-19 09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
Jun-11-19 06:00AM  Is the Newest Gene Editing Stock a Buy? Motley Fool
Jun-10-19 09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-09-19 07:27AM  Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy? Motley Fool
Jun-07-19 09:54AM  Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion Benzinga +15.11%
09:54AM  Vertex Pharmaceuticals Bets on Gene Therapy With New Acquisition Barrons.com
09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
05:12PM  Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics Business Wire
May-31-19 08:25AM  Vertex Selects Triple Combo Regimen for Regulatory Submission Zacks
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-29-19 07:55PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns a provisional rating to One CMBS class of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-28-19 03:56PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns provisional ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
May-24-19 12:23PM  Highlights from CNBC's Healthy Returns conference CNBC
May-23-19 11:44AM  Genetics, CRISPR and Medical Ethics: CEO of Synthego, CRISPR Therapeutics and Stanford Medical's Hurlbut at Healthy Returns CNBC Videos -5.18%
May-21-19 05:22PM  'We as a species need to come to terms' with CRISPR technology as China awaits birth of third genetically modified baby CNBC
May-13-19 09:27AM  5 Growthy Biotech Stocks to Buy Despite the Scrutiny InvestorPlace -7.00%
May-08-19 08:27AM  Why CRISPR Therapeutics Gained 13.4% in April Motley Fool
May-01-19 07:40PM  Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP)? Insider Monkey
11:46AM  Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates Zacks
07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Apr-29-19 04:01PM  CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-27-19 01:00PM  Better Buy: Editas Medicine vs. CRISPR Therapeutics Motley Fool
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
09:26AM  Some CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Are Down 19% Simply Wall St.
Apr-23-19 08:44AM  2 Best Biotech Buyout Plays Motley Fool
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -6.78%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:18PM  CRISPR Therapeutics Attempts Breakout on FDA Fast Track Investopedia +5.20%
11:19AM  UPenn Treats First Cancer Patients in Crispr-Based Trial Bloomberg
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia GlobeNewswire
Apr-15-19 02:00PM  Four Companies Could Power The New Genomics ETF ETF Trends
Apr-03-19 09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
Apr-01-19 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-28-19 08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Mar-27-19 01:13PM  8 Genomic Testing Stocks That Can Ease the Sting of Theranos InvestorPlace
Mar-26-19 06:07PM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace
06:00AM  CRISPR and Vertex- Front-Runners in Gene-Therapy MoneyShow
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
10:49AM  Has CRISPR Therapeutics AG (NASDAQ:CRSP) Got Enough Cash? Simply Wall St.
Mar-06-19 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire -6.07%
Mar-04-19 11:36AM  Why NOW Is the Time to Buy Gene Therapy Stocks InvestorPlace
09:15AM  S&P Reclaims 2800; NASDAQs Streak Hits 10 Weeks Zacks
Feb-27-19 04:53PM  CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire
09:58AM  CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again InvestorPlace
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks -8.70%
10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
09:15AM  Deal on the Way Now that Deadline is Delayed? Zacks
Feb-25-19 04:31PM  Why Danaher, CRISPR Therapeutics, and Clementia Pharmaceuticals Jumped Today Motley Fool +25.20%
04:12PM  Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient Investor's Business Daily
02:21PM  Here's Why Gene Therapy Stocks Are Soaring Today Motley Fool
10:11AM  Crispr Infuses First Human in Landmark Gene-Editing Study Bloomberg
08:02AM  CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
08:00AM  CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 GlobeNewswire
12:58AM  [$$] Crispr Therapeutics treats its first human with gene editing Financial Times
Feb-23-19 09:15AM  Strong Friday Close Secures a 9th Week in the Green Zacks
Feb-21-19 07:00AM  CRISPR Therapeutics Proposes New Members to the Board of Directors GlobeNewswire
Feb-19-19 07:00AM  CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement GlobeNewswire
Feb-14-19 12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 07:49AM  Jim Cramer Gives His Opinion On Cronos, Etsy And More Benzinga
Feb-11-19 12:36PM  Here's Why CRISPR Therapeutics Rose 13.5% in January Motley Fool
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool -8.73%
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, the company engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, duchenne muscular dystrophy, cystic fibrosis, and hurler syndrome. It partners with biopharma companies, academic centers, universities, and other organizations. The company has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to develop and commercialize products for the treatment of Duchenne M. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klein Lawrence OttoChief Business OfficerJul 11Option Exercise5.868,42149,34728,421Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 11Sale50.018,421421,17120,000Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Option Exercise5.8611,57967,85331,579Jul 12 04:13 PM
Novak RodgerPresidentJul 10Sale50.0050,0002,500,065848,007Jul 12 04:10 PM
Klein Lawrence OttoChief Business OfficerJul 10Sale50.0211,579579,18220,000Jul 12 04:13 PM
Kulkarni SamarthChief Executive OfficerJun 17Option Exercise1.8120,00036,200185,801Jun 19 04:15 PM
Kulkarni SamarthChief Executive OfficerJun 17Sale46.0020,000920,000165,801Jun 19 04:15 PM
Novak RodgerPresidentJun 10Sale45.0050,0002,250,000898,007Jun 12 04:16 PM
Kulkarni SamarthChief Executive OfficerApr 29Option Exercise1.8120,00036,200186,542May 01 04:05 PM
Kulkarni SamarthChief Executive OfficerApr 29Sale42.0320,000840,600166,542May 01 04:05 PM
Novak RodgerPresidentMar 04Sale40.4576,5273,095,240948,007Mar 05 05:59 PM
Novak RodgerPresidentMar 01Sale40.018,693347,7961,024,534Mar 05 05:59 PM
Novak RodgerPresidentFeb 25Sale40.0014,780591,2331,033,227Feb 27 04:10 PM
Novak RodgerPresidentJan 09Sale35.0182,6902,894,9771,048,007Jan 10 04:09 PM
Novak RodgerPresidentJan 08Sale35.0917,310607,4081,130,697Jan 10 04:09 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 27Buy24.9527,461685,1165,380,940Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 26Buy24.8912,737317,0775,353,479Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 24Buy24.5868,0001,671,4825,340,742Dec 26 04:35 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 21Buy22.5822,742513,4785,272,742Dec 26 04:35 PM
EMSTER KURT VONDirectorDec 18Sale29.7069,9252,077,1011,164,268Dec 19 04:22 PM
EMSTER KURT VONDirectorDec 17Sale33.173,00999,7971,234,193Dec 19 04:22 PM
Kulkarni SamarthChief Executive OfficerDec 07Option Exercise1.8121,50038,915167,290Dec 11 04:29 PM
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM